Clinical data | |
---|---|
Trade names | Diabeta, Glynase, Micronase, others [1] |
Other names | Glyburide ( USAN US) |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a684058 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | Extensive |
Metabolism | Liver hydroxylation ( CYP2C9-mediated) |
Elimination half-life | 10 hours |
Excretion | Kidney and bile duct |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.030.505 |
Chemical and physical data | |
Formula | C23H28ClN3O5S |
Molar mass | 494.00 g·mol−1 |
3D model ( JSmol) | |
Melting point | 169 to 170 °C (336 to 338 °F) |
| |
| |
(verify) |
Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. [1] It is recommended that it be taken together with diet and exercise. [1] It may be used with other antidiabetic medication. [1] It is not recommended for use by itself in type 1 diabetes. [1] It is taken by mouth. [1]
Common side effects include nausea and heartburn. [1] Serious side effects may include angioedema and low blood sugar. [1] It is generally not recommended during pregnancy but can be used during breastfeeding. [3] It is in the sulfonylureas class of medications and works by increasing the release of insulin from the pancreas. [1]
Glibenclamide was discovered in 1969 and approved for medical use in the United States in 1984. [4] [1] It is available as a generic medication. [3] In 2021, it was the 214th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [5] [6]
Glibenclamide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [2]
It is not as good as either metformin or insulin in those who have gestational diabetes. [7]
Frequently reported side effects include: nausea, heartburn, weight gain, and bloating. [8] The medication is also a major cause of medication-induced hypoglycemia. The risk is greater than with other sulfonylureas. [9]
Glibenclamide may be not recommended in those with G6PD deficiency, as it may cause acute hemolysis. [10]
It is generally not recommended during pregnancy but can be used during breastfeeding. [3]
The medication, a sulfonylurea, works by binding to and inhibiting the ATP-sensitive potassium channels (KATP) inhibitory regulatory subunit sulfonylurea receptor 1 (SUR1) [11] in pancreatic beta cells. This inhibition causes cell membrane depolarization, opening voltage-dependent calcium Channels. [12]
This results in an increase in intracellular calcium in the pancreatic beta cell and subsequent stimulation of insulin release. [13]
After a cerebral ischemic insult, the blood–brain barrier is broken and glibenclamide can reach the central nervous system. Glibenclamide has been shown to bind more efficiently to the ischemic hemisphere. [14] Moreover, under ischemic conditions SUR1, the regulatory subunit of the KATP- and the NCCa-ATP-channels, is expressed in neurons, astrocytes, oligodendrocytes, endothelial cells [15] and by reactive microglia. [14]
As per the research papers, this sulphonylurea drugs also has extra hepatic effects. It works by inhibiting the enzyme Carnityl Acyl Transferase I (CAT-I) indirectly which is present in the mitochondria. This prevents the transport of long chain fatty acids into the mitochondria for beta-oxidation. This prevents hyperglycemia for which it is prescribed. [16] [17]
It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). [18]
Glibenclamide is available as a generic medication, is manufactured by many pharmaceutical companies and is sold under many brand names including Gliben-J, Daonil, [19] Diabeta, [20] Euglucon, Gilemal, Glidanil, Glybovin, Glynase, Maninil, Micronase and Semi-Daonil. It is also available in a fixed-dose combination drug with metformin that is sold under various trade names, e.g. Bagomet Plus, Benimet, Glibomet, Gluconorm, Glucored, Glucovance, Metglib and many others. [21]
Clinical data | |
---|---|
Trade names | Diabeta, Glynase, Micronase, others [1] |
Other names | Glyburide ( USAN US) |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a684058 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | Extensive |
Metabolism | Liver hydroxylation ( CYP2C9-mediated) |
Elimination half-life | 10 hours |
Excretion | Kidney and bile duct |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.030.505 |
Chemical and physical data | |
Formula | C23H28ClN3O5S |
Molar mass | 494.00 g·mol−1 |
3D model ( JSmol) | |
Melting point | 169 to 170 °C (336 to 338 °F) |
| |
| |
(verify) |
Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. [1] It is recommended that it be taken together with diet and exercise. [1] It may be used with other antidiabetic medication. [1] It is not recommended for use by itself in type 1 diabetes. [1] It is taken by mouth. [1]
Common side effects include nausea and heartburn. [1] Serious side effects may include angioedema and low blood sugar. [1] It is generally not recommended during pregnancy but can be used during breastfeeding. [3] It is in the sulfonylureas class of medications and works by increasing the release of insulin from the pancreas. [1]
Glibenclamide was discovered in 1969 and approved for medical use in the United States in 1984. [4] [1] It is available as a generic medication. [3] In 2021, it was the 214th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [5] [6]
Glibenclamide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [2]
It is not as good as either metformin or insulin in those who have gestational diabetes. [7]
Frequently reported side effects include: nausea, heartburn, weight gain, and bloating. [8] The medication is also a major cause of medication-induced hypoglycemia. The risk is greater than with other sulfonylureas. [9]
Glibenclamide may be not recommended in those with G6PD deficiency, as it may cause acute hemolysis. [10]
It is generally not recommended during pregnancy but can be used during breastfeeding. [3]
The medication, a sulfonylurea, works by binding to and inhibiting the ATP-sensitive potassium channels (KATP) inhibitory regulatory subunit sulfonylurea receptor 1 (SUR1) [11] in pancreatic beta cells. This inhibition causes cell membrane depolarization, opening voltage-dependent calcium Channels. [12]
This results in an increase in intracellular calcium in the pancreatic beta cell and subsequent stimulation of insulin release. [13]
After a cerebral ischemic insult, the blood–brain barrier is broken and glibenclamide can reach the central nervous system. Glibenclamide has been shown to bind more efficiently to the ischemic hemisphere. [14] Moreover, under ischemic conditions SUR1, the regulatory subunit of the KATP- and the NCCa-ATP-channels, is expressed in neurons, astrocytes, oligodendrocytes, endothelial cells [15] and by reactive microglia. [14]
As per the research papers, this sulphonylurea drugs also has extra hepatic effects. It works by inhibiting the enzyme Carnityl Acyl Transferase I (CAT-I) indirectly which is present in the mitochondria. This prevents the transport of long chain fatty acids into the mitochondria for beta-oxidation. This prevents hyperglycemia for which it is prescribed. [16] [17]
It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). [18]
Glibenclamide is available as a generic medication, is manufactured by many pharmaceutical companies and is sold under many brand names including Gliben-J, Daonil, [19] Diabeta, [20] Euglucon, Gilemal, Glidanil, Glybovin, Glynase, Maninil, Micronase and Semi-Daonil. It is also available in a fixed-dose combination drug with metformin that is sold under various trade names, e.g. Bagomet Plus, Benimet, Glibomet, Gluconorm, Glucored, Glucovance, Metglib and many others. [21]